Shaila Shabbir
Overview
Explore the profile of Shaila Shabbir including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
57
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Barth A, Perry C, Shabbir S, Zamek-Gliszczynski M, Thomas S, Dumont E, et al.
Clin Transl Sci
. 2023 Jan;
16(4):647-661.
PMID: 36642822
Gepotidacin is a novel triazaacenaphthylene antibiotic in phase III development. Based on nonclinical in vitro characterization of gepotidacin metabolism, two phase I studies were conducted in healthy participants to investigate...
2.
Barth A, Hossain M, Perry C, Gross A, Ogura H, Shabbir S, et al.
Clin Pharmacol Drug Dev
. 2022 Dec;
12(1):38-56.
PMID: 36468634
Gepotidacin is a novel, bactericidal, first-in-class triazaacenaphthylene antibiotic in late-phase development for uncomplicated urinary tract infection and uncomplicated urogenital gonorrhea. Two clinical studies were conducted to assess the pharmacokinetics (PK)...
3.
Daley-Yates P, Keppler B, Brealey N, Shabbir S, Singh D, Barnes N
Eur J Endocrinol
. 2022 Jul;
187(3):413-427.
PMID: 35900313
Objective: The aim of this study was toidentify dose-related systemic effects of inhaled glucocorticoids (GCs) on the global metabolome. Design And Methods: Metabolomics/lipidomic analysis from plasma was obtained from 54...
4.
Siddall H, Quint D, Pandya H, Powley W, Shabbir S, Hohlfeld J, et al.
PLoS One
. 2020 Nov;
15(11):e0240964.
PMID: 33166307
Background: Allergic asthma is a heterogenous disorder predominantly driven by a type 2 inflammatory response to aeroallergens. Therapeutic modulation to rebalance these type 2 responses may offer clinical benefit for...
5.
Daley-Yates P, Brealey N, Thomas S, Austin D, Shabbir S, Harrison T, et al.
Br J Clin Pharmacol
. 2020 Jun;
87(2):483-493.
PMID: 32484940
Aims: To compare the airway potency, systemic activity and therapeutic index of three inhaled corticosteroids that differ in glucocorticoid receptor binding affinity, physicochemical and pharmacokinetic properties. Methods: This escalating-dose, placebo-controlled,...
6.
Shabbir S, Pouliquen I, Bentley J, Bradford E, Kaisermann M, Albayaty M
Clin Pharmacol Drug Dev
. 2019 Jul;
9(3):375-385.
PMID: 31317668
This study compared the pharmacokinetic (PK) profile of a new liquid formulation of mepolizumab with the established lyophilized formulation. In this open-label, parallel-group, single-dose study (NCT03014674; GSK ID: 204958), healthy...
7.
ONeill B, Dodds C, Miller S, Gupta A, Lawrence P, Bullman J, et al.
Hum Psychopharmacol
. 2019 May;
34(3):e2694.
PMID: 31124194
Objective: This double-blind, randomised, placebo-controlled, two-part study assessed the impact of GSK2981710, a medium-chain triglyceride (MCT) that liberates ketone bodies, on cognitive function, safety, and tolerability in healthy older adults....
8.
Huiban M, Coello C, Wu K, Xu Y, Lewis Y, Brown A, et al.
Mol Imaging Biol
. 2016 Jul;
19(1):153-161.
PMID: 27402093
Purpose: GSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase A (Lp-PLA), which was in development as a potential treatment for Alzheimer's disease (AD). In order to refine therapeutic...